In the published article, there were errors in Figure 4 as published. The graph included incorrect labeling of livmoniplimab doses for a few patients, including for the patient with deepest response (corrected from livmoniplimab 100mg to livmoniplimab 1500mg) in Figure 4B. The corrected Figure 4 and its caption appear below.
Figure 4
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
advanced solid tumors, TGF-ß1, GARP, immunotherapy, anti-PD-1 antibody, combination drug therapy, investigational therapies, tumor microenvironment (TME)
Citation
Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller KD, Kao S, Kongpachith S, Tribouley C, Graham M, Stoll B, Patel M, Sahtout M, Blaney M, Leibman R, Golan T and Tolcher A (2025) Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors. Front. Oncol. 14:1544394. doi: 10.3389/fonc.2024.1544394
Received
12 December 2024
Accepted
19 December 2024
Published
31 January 2025
Volume
14 - 2024
Edited and reviewed by
Cory L. Brooks, California State University, Fresno, United States
Updates
Copyright
© 2025 Shimizu, Powderly, Abdul Razak, LoRusso, Miller, Kao, Kongpachith, Tribouley, Graham, Stoll, Patel, Sahtout, Blaney, Leibman, Golan and Tolcher.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Toshio Shimizu, tosshimi@ncc.go.jp
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.